Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 2/20 | 0.35 |
| ▸ | POLRMT | O00411 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | POLG | P54098 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26651178 | 0.93 | POLRMT (0.33) | RNASELPOLRMTABCB11POLA1POLG | |
| SCHEMBL26651233 | 0.90 | POLRMT (0.33) | RNASELPOLRMT | |
| SCHEMBL24917203 | 0.89 | POLRMT (0.32) | RNASELPOLRMTABCB11POLA1POLG | |
| SCHEMBL25607768 | 0.89 | POLRMT (0.34) | POLRMTTMPRSS2 | |
| SCHEMBL24916851 | 0.89 | RNASEL (0.35) | RNASELPOLRMTABCB11POLA1POLG | |
| SCHEMBL24917155 | 0.88 | TMPRSS2 (0.45) | RNASELPOLRMTABCB11POLA1POLG | |
| SCHEMBL25912699 | 0.87 | RNASEL (0.32) | RNASELPOLRMTABCB11POLA1POLG | |
| SCHEMBL24917302 | 0.86 | POLRMT (0.35) | RNASELPOLRMTABCB11POLA1POLG | |
| SCHEMBL25912660 | 0.86 | RNASEL (0.32) | RNASELABCB11POLA1POLGFAP | |
| SCHEMBL26328722 | 0.86 | POLRMT (0.34) | POLRMTTMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | MIRACURE BIOTECHNOLOGY LTD (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | RNASEL 152/4885POLRMT 138/4885ABCB11 445/4885 |
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | PNP, MTAP, TYMP | RNASEL 57/4885POLRMT 210/4885ABCB11 1012/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | RNASEL 152/4885POLRMT 138/4885ABCB11 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.